Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Targeting Latent Cytomegalovirus in Donor Lungs Using Ex Vivo Lung Perfusion

EF 2017-18

Résumé
Lung transplantation is a life-saving treatment for patients with end-stage lung diseases. Unfortunately, the waiting list for a transplant has increased in the last years and there are no organs for everyone on the list and patients end up dying waiting for lungs. With that on mind, there's a well established platform already used in the clinical field called Ex Vivo Lung Perfusion. This platform aims to treat and recover marginal lungs outside of the body, making them good for transplantation. Cytomegalovirus (CMV) is a common virus that affects around 50% of population. It's a non threatening virus for people with good immunological status, but in immunodeficient patients it becomes a big problem. Lung transplant patients receive immunosuppressive drugs to allow the body to accept the foreing graft better, so this patients are immunodeficient. CMV is related with poorer clinical outcomes in lung transplantation and the treatments used today are not enough to treat all the infections. There's a novel therapy that targets specifically cells infected with CMV and had good results in cell culture lines and in mice. My objective is to use this treatment - Fusion Toxin Protein - during Ex Vivo Lung Perfusion to treat CMV in lung tissue and reduce CMV infections in lung recipients. I hypothesize that this treatment will clear all the cells infected with cytomegalovirus and will decrease CMV infections post-transplantation resulting in better outcomes and increase rate survival for lung transplant patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
386492
Name
Ribeiro Rafaela
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting Latent Cytomegalovirus in Donor Lungs Using Ex Vivo Lung Perfusion
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cytomegalovirus; Ex Vivo Lung Perfusion; Infectious Disease; Lung Transplantation; Organ Preservation; Thoracic Surgery
Abstract
Lung transplantation is a life-saving treatment for patients with end-stage lung diseases. Unfortunately, the waiting list for a transplant has increased in the last years and there are no organs for everyone on the list and patients end up dying waiting for lungs. With that on mind, there's a well established platform already used in the clinical field called Ex Vivo Lung Perfusion. This platform aims to treat and recover marginal lungs outside of the body, making them good for transplantation. Cytomegalovirus (CMV) is a common virus that affects around 50% of population. It's a non threatening virus for people with good immunological status, but in immunodeficient patients it becomes a big problem. Lung transplant patients receive immunosuppressive drugs to allow the body to accept the foreing graft better, so this patients are immunodeficient. CMV is related with poorer clinical outcomes in lung transplantation and the treatments used today are not enough to treat all the infections. There's a novel therapy that targets specifically cells infected with CMV and had good results in cell culture lines and in mice. My objective is to use this treatment - Fusion Toxin Protein - during Ex Vivo Lung Perfusion to treat CMV in lung tissue and reduce CMV infections in lung recipients. I hypothesize that this treatment will clear all the cells infected with cytomegalovirus and will decrease CMV infections post-transplantation resulting in better outcomes and increase rate survival for lung transplant patients.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ribeiro, Rafaela
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~